查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1858138

依給藥途徑、適應症、藥物類型、劑型和患者年齡層分類的皮質類固醇治療市場－2025-2032年全球預測

Corticosteroids Therapy Market by Route Of Administration, Indication, Drug Type, Dosage Form, Patient Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，皮質類固醇治療市場將成長至 97.3 億美元，複合年成長率為 7.99%。

關鍵市場統計數據
基準年 2024 52.6億美元
預計年份：2025年 56.9億美元
預測年份 2032 97.3億美元
複合年成長率 (%) 7.99%

本文簡明扼要地總結了重新定義皮質類固醇療法的臨床、商業性和監管因素，並為產業相關人員的策略決策提供指導。

皮質類固醇在多個治療領域仍是基石，了解其不斷變化的臨床、商業性和監管環境對於策略決策至關重要。本執行摘要了影響皮質類固醇治療的當代動態，重點闡述了給藥方式、治療適應症、產品系列、人口結構變化和地緣政治影響如何共同塑造臨床實踐和供應鏈韌性。

臨床實踐正在不斷發展，以最佳化皮質類固醇的劑量、給藥途徑和聯合用藥策略，從而在最大限度減少副作用的同時，最大限度地提高療效。製劑科學和給藥技術的進步支持了吸入和局部治療的廣泛應用，而已確立的全身性用藥在急性期和維持治療中仍然發揮著重要作用。同時，監管審查和不斷變化的藥物安全檢測警戒要求迫使生產商加大對強力的安全監測和核准後證據收集的投入。

在商業性，相關人員面臨著一個差異化、藥品目錄定位和供應安全至關重要的局面。支付方和醫療服務提供者都要求提供相對療效和經濟價值的證據，而採購團隊也越來越重視原料藥採購和生產能力的上游風險。本摘要旨在為產品組合經理、商業負責人和供應鏈策略家提供切實可行的見解，幫助他們有效應對這一複雜多變的環境。

技術創新、不斷完善的指南和供應鏈現代化如何改變皮質類固醇治療的臨床實踐和商業策略

由於技術創新、臨床指南的不斷改進以及供應鏈的重組，皮質類固醇藥物市場正在發生變化。近期製劑的創新，透過吸入裝置和先進的局部製劑，提高了局部給藥的效率和安全性，從而拓展了治療套件。同時，藥物動力學和輔料科學的進步，使得更人性化的局部方案成為可能，提高了患者的依從性，並拓寬了治療選擇。

臨床指引正日益重視以病人為中心的風險評估，從而針對慢性病和急性病提出更細緻的建議。這一趨勢激發了人們對聯合治療和階梯式治療策略的興趣，這些策略旨在維持疾病控制的同時，降低累積全身暴露量。隨著相關人員的積極回應，商業模式也在進行調整，將累積療效和真實世界證據置於短期商業利益之上。

供應鏈現代化和對區域製造業的投資正在重塑供應商關係和籌資策略。各組織優先考慮供應商透明度、雙重採購和庫存緩衝，以降低中斷風險。同時，數位健康解決方案和遠端監測正在加強依從性追蹤和上市後監測，為製造商提供與病人參與和價值展示的新管道。總而言之，這些變化正在創造一個更具韌性、以證據主導的市場環境，在這個環境中，治療方法差異化和供應完整性至關重要。

評估美國關稅調整對皮質類固醇供應鏈、採購動態和製造韌性的策略影響（截至2025年）

美國加徵關稅和調整貿易政策將對皮質類固醇價值鏈產生多方面影響，波及下游的籌資策略、生產佈局和商業實踐。關稅有可能增加進口原料藥、輔料和成品藥的到岸成本，迫使生產商和經銷商重新評估其供應商組合和合約條款。為此，許多公司正在權衡近岸外包和本土生產的經濟效益，以及建立合規藥品製造地帶來的營運複雜性。

除了成本之外，關稅還會影響供應商的談判動態和庫存計劃。採購團隊可能會延長前置作業時間，在不同司法管轄區內分散供應商，並增加安全庫存以應對政策引起的波動。這些營運調整往往會波及與支付方和醫療服務提供者的價格談判，迫使製造商在利潤率維持和藥品目錄競爭力之間尋求平衡。此外，與關稅、藥品分類和合規相關的行政負擔也會延長產品上市時間，並使全球供應鏈同步更加複雜。

政策變化也凸顯了垂直整合和策略聯盟的重要性。企業可能會尋求長期供應協議、共同投資生產能力或建立區域夥伴關係，以確保關鍵投入並維持服務的連續性。貿易夥伴之間的監管相容性和關稅分類清晰度成為採購決策的關鍵因素。綜上所述，這些動態表明，企業需要積極主動地跨部門應對關稅帶來的壓力，以保障市場進入和商業性生存能力。

跨給藥途徑、適應症、藥物類別、劑型和年齡層進行多方面細分分析，以幫助進行有針對性的開發和商業化。

精細化的市場區隔架構能夠清楚展現臨床需求、製劑創新與商業策略之間的交集，進而促進目標明確的產品開發與上市規劃。給藥途徑的區分至關重要，因為吸入、注射、口服和局部用藥在研發、監管和依從性方面都存在差異。吸入方式又可進一步細分為乾粉吸入器、定量吸入器和霧化器平台，而注射液則需要關注肌肉注射、靜脈注射和皮下注射的細微差別。口服類固醇，每種劑型都會影響兒童的接受度和劑量準確度。

過敏性鼻炎和氣喘需要療效顯著且局部用藥效果最佳的吸入和鼻內製劑，而皮膚病則優先考慮安全性良好的外用藥物。發炎性腸道疾病和類風濕性關節炎通常需要具有控制釋放特性且需進行全面安全監測的全身用藥。藥物分類突顯了Budesonide、Methylprednisolone、氫化可的松、Hydrocortisone和潑尼松等藥物之間的競爭動態和臨床差異，每種藥物都具有不同的藥理學特性和耐受性，從而影響處方行為。

按劑型（乳膏劑、注射、混懸劑、錠劑）進行細分，會與給藥途徑和適應症交叉，從而決定生產複雜性和患者體驗。以患者族群（成人、老年人和兒童）進行細分，則凸顯了針對不同年齡層的製劑、兒童偏好以及考慮合併症和多重用藥的老年給藥策略的必要性。整合這些視角，可以實現生命週期管理、臨床證據產生和商業性定位的一致性，從而使產品屬性與相關人員的需求保持一致。

美洲、中東和非洲以及亞太地區的監管差異、支付方結構和製造地將如何推動差異化的打入市場策略？

區域動態影響臨床實踐模式、監管預期和供應鏈設計，因此，市場准入和生命週期管理需要採取細緻入微的方法。在美洲，醫療保健系統展現出私營和公共支付模式，這些模式優先考慮處方集談判、真實世界療效和供應可靠性。該地區還強調差異化證據和合約履行，並擁有強大的生產能力和完善的分銷網路。歐洲、中東和非洲地區（EMEA）的管理體制和進入途徑各不相同。區域中心和本地生產有助於市場進入，但臨床指南和報銷框架在各個細分市場之間存在顯著差異。在這些地區，滿足不同臨床醫生的偏好並適應當地的藥物安全檢測標準至關重要。

亞太地區是一個充滿活力的市場，新興市場和成熟市場交錯分佈，監管嚴格程度和成本敏感度各不相同。快速的都市化以及慢性呼吸系統疾病和皮膚疾病盛行率的上升，催生了對成熟和新型皮質類固醇療法的需求。在整個亞太地區，跨境供應鏈風險、監管協調工作以及不斷變化的患者期​​望，凸顯了靈活的生產佈局、可調整的定價模式以及有針對性的證據生成對於支持市場准入和長期應用的重要性。

競爭動態和策略能力如何影響皮質類固醇領域的產品差異化、供應連續性和主導商業化

在競爭激烈的市場環境中，治療效果、供應可靠性和實證醫學證據決定製藥業的商業性成敗。擁有整合生產網路的傳統製藥公司憑藉其規模優勢和監管經驗，維持著涵蓋全身和局部類固醇治療的廣泛產品組合。同時，專注於藥物研發和生物技術的公司則致力於製劑改進、器械整合以及特定適應症的開發，以安全性和患者便利性為核心，構建差異化的提案主張。

隨著支付方要求提供可靠的真實世界證據和療效數據以證明處方箋報銷的合理性，商業團隊與臨床開發團隊之間的合作變得日益重要。策略夥伴關係、共同開發契約和製造外包關係是加速新型給藥系統和替代劑型上市並控制資本密集度的常用機制。此外，企業也在藥物安全檢測、衛生經濟學和病患援助計畫方面進行投資，以加強產品定位並維持慢性病患者的用藥依從性。總而言之，競爭優勢源自於將臨床差異化與靈活的生產製造和嚴謹的上市後證據產生結合。

為製造商和相關人員提供切實可行的策略指南，以協調創新、供應鏈韌性和證據生成，同時管理商業性風險。

產業領導者應採取積極主動的策略，使臨床創新與供應鏈韌性和支付者期望保持一致。優先投資於製劑平台和器械整合，以增強局部給藥、減少全身暴露並提高病患依從性。同時，透過多元化採購、簽訂長期合約和選擇性垂直整合，加強與關鍵原料藥和輔料供應商的關係，以降低供應中斷風險並確保供應的連續性。

我們將結合務實的真實世界臨床試驗和隨機對照試驗，加強證據生成，以捕捉長期安全性、依從性模式和健康經濟學結果。我們將利用這些數據，在與支付方和醫療保健系統的談判中，提出差異化的提案主張。在營運方面，我們將部署先進的需求感知工具和情境規劃，以應對貿易政策變化和物流限制。最後，我們將實施嚴謹的產品組合管理，使治療重點與未滿足的臨床需求和人口趨勢保持一致，同時尋求策略夥伴關係，以加速新型製劑和給藥系統的上市速度。

我們採用透明的三管齊下的研究途徑，結合臨床醫生訪談、監管審查和營運分析，以檢驗臨床和商業領域的見解。

本研究整合了一手和二手資料，旨在從臨床、商業和供應鏈等多個層面全面觀點皮質類固醇療法。一手資料包括對呼吸科、皮膚科和胃腸科的臨床醫生、採購負責人和法規事務專業人員的結構化訪談，並輔以與生產和品質專家的私人諮詢。二級資訊來源包括同行評審文獻、監管指南、藥典標準以及公開的產品核可和安全通告資訊。

分析方法優先考慮將定性見解與已記錄的法律規範進行交叉檢驗。該方法強調三角驗證，即將訪談觀察結果與已發布的指南和生產實踐進行比對，以確保解釋的可靠性。情境分析用於檢驗貿易政策變化對採購和分銷的營運影響，證據綜合則著重於將產品屬性與臨床需求和病患群體特徵相匹配。資料管治實踐和調查方法的透明度為所有研究結果奠定了基礎，以確保其可重複性和對決策者的實際意義。

總結報告強調，臨床創新、實證商業化和供應鏈韌性的整合是未來成功的決定性因素。

皮質類固醇療法正處於持久臨床效用與日益成長的安全性、差異化和供應需求之間的十字路口。製劑和給藥技術的進步，以及不斷發展的臨床管理，為有針對性的創新創造了機遇，這些創新既能改善患者療效，又能滿足支付方和醫療服務提供方的優先事項。同時，地緣政治和貿易政策的發展正將供應鏈考量提升至策略要務的高度，使韌性成為商業規劃的核心要素。

因此，決策者應在臨床差異化投資與確保上​​游投入和生產連續性的務實措施之間取得平衡。產生能夠證明真實世界獲益和成本效益的證據，對於處方討論和長期應用至關重要。總之，能夠有效整合臨床科學、法規遵循和運作靈活性，從而提供滿足患者、臨床醫生和醫療保健系統需求的皮質類固醇療法的機構，將會成功。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 標靶吸入性皮質類固醇製劑對重度氣喘治療成本與療效的影響
  • 新型小分子糖皮質激素調變器旨在減少慢性發炎疾病的全身性副作用
  • 擴大生物類似注射用皮質類固醇的供應，以改善新興市場的可及性並促進價格競爭
  • 開發基於奈米技術的皮質類固醇藥物遞送系統，以增強眼部和皮膚的治療效果
  • 整合數位健康平台，用於遠端監測類風濕性關節炎患者生物製劑皮質類固醇治療的依從性
  • 推廣皮質類固醇和免疫調節劑聯合治療異位性皮膚炎，並提高患者依從性
  • 監管改革將加速新型吸入皮質類固醇療法在兒童氣喘患者的核准途徑
  • 基因表現分析技術的進步將指導自體自體免疫疾病全身性皮質類固醇治療方案的個人化給藥策略

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依給藥途徑分類的皮質類固醇治療市場

  • 吸入
    • 乾粉吸入器
    • 定量吸入器
    • 噴霧器
  • 注射
    • 肌肉內注射
    • 靜脈注射
    • 皮下
  • 口服
    • 暫停
    • 藥片
  • 局部的
    • 奶油
    • 洗劑
    • 軟膏

9. 依適應症分類的皮質類固醇治療市場

  • 過敏性鼻炎
  • 氣喘
  • 皮膚病
  • 發炎性腸道疾病
  • 類風濕性關節炎

第10章 依藥物類型分類的皮質類固醇治療市場

  • Budesonide
  • 地塞米松
  • Hydrocortisone
  • Methylprednisolone
  • 強的松

第11章：以劑型分類的皮質類固醇治療市場

  • 奶油
  • 注射
  • 暫停
  • 藥片

12. 依患者年齡層分類的皮質類固醇治療市場

  • 成人版
  • 晚年
  • 孩子們

13. 各地區皮質類固醇治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 按組別分類的皮質類固醇治療市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國皮質類固醇治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • GlaxoSmithKline plc
    • AstraZeneca plc
    • Novartis AG
    • Sanofi SA
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd
    • Sun Pharmaceutical Industries Ltd
    • Mylan NV
    • Sandoz International GmbH
Product Code: MRR-C002B1C9976A

The Corticosteroids Therapy Market is projected to grow by USD 9.73 billion at a CAGR of 7.99% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.26 billion
Estimated Year [2025] USD 5.69 billion
Forecast Year [2032] USD 9.73 billion
CAGR (%) 7.99%

A concise synthesis of clinical, commercial, and regulatory forces redefining corticosteroid therapy and guiding strategic decision-making for industry stakeholders

Corticosteroids remain a foundational pillar across multiple therapeutic areas, and understanding their evolving clinical, commercial, and regulatory context is essential for strategic decision-making. This executive summary synthesizes contemporary dynamics affecting corticosteroid therapy, emphasizing how delivery modalities, therapeutic indications, product portfolios, demographic shifts, and geopolitical influences converge to shape clinical practice and supply chain resilience.

Clinical practice continues to refine corticosteroid use toward precision in dosing, route selection, and combination strategies that optimize efficacy while mitigating adverse effects. Advances in formulation science and delivery technologies have supported expanded usage in inhalation and topical care, while established systemic agents retain importance in acute and maintenance settings. Concurrently, regulatory scrutiny and evolving pharmacovigilance expectations drive manufacturers to invest in robust safety monitoring and post-authorization evidence generation.

Commercially, stakeholders face a landscape where differentiation, formulary positioning, and supply security are primary considerations. Payers and providers demand evidence of comparative benefit and economic value, and procurement teams increasingly assess upstream vulnerabilities in API sourcing and manufacturing capacity. Throughout this summary, emphasis is placed on actionable insights for portfolio managers, commercial leads, and supply chain strategists seeking to navigate this multifaceted environment effectively.

How technological innovation, guideline evolution, and supply chain modernization are jointly transforming clinical practice and commercial strategy for corticosteroid therapies

The corticosteroid landscape is undergoing transformative shifts driven by technological innovation, evolving clinical guidelines, and supply chain realignment. Recent formulation innovations have expanded the therapeutic toolkit, with inhalation devices and refined topical formulations enhancing local delivery and safety margins. At the same time, improvements in pharmacokinetics and excipient science have enabled more patient-friendly dosing regimens that support adherence and broaden treatment windows.

Clinical guidelines are progressively integrating patient-centered risk assessments, resulting in more nuanced recommendations across chronic and acute indications. This trend has stimulated interest in combination therapies and step-down strategies that maintain disease control while reducing cumulative systemic exposure. As stakeholders respond, commercial models are adapting to emphasize long-term outcomes and real-world evidence rather than short-term transactional gains.

Supply chain modernization and regional manufacturing investments are reshaping vendor relationships and procurement strategies. Organizations are prioritizing supplier transparency, dual sourcing, and inventory buffers to mitigate disruption risk. In parallel, digital health solutions and remote monitoring are enhancing adherence tracking and post-marketing surveillance, offering manufacturers new channels for patient engagement and value demonstration. Taken together, these shifts are fostering a more resilient, evidence-driven market environment in which therapeutic differentiation and supply integrity are paramount.

Assessing the strategic repercussions of United States tariff adjustments on corticosteroid supply chains, procurement dynamics, and manufacturing resilience through 2025

The imposition of tariffs and trade policy adjustments in the United States have a multifaceted impact on the corticosteroid value chain, with downstream implications for procurement strategies, manufacturing footprints, and commercial conduct. Tariffs can increase landed costs for imported APIs, excipients, and finished dosage forms, prompting manufacturers and distributors to reassess supplier portfolios and contractual terms. In response, many organizations are weighing the economics of nearshoring or onshoring manufacturing capacity against the operational complexities of establishing compliant pharmaceutical production sites.

Beyond cost considerations, tariffs influence supplier negotiation dynamics and inventory planning. Procurement teams may extend lead times, diversify suppliers across jurisdictions, and increase safety stock to absorb policy-driven volatility. Such operational shifts often cascade into pricing discussions with payers and providers, where manufacturers must balance margin preservation with formulary competitiveness. Additionally, administrative burdens associated with customs, classification, and compliance can lengthen product launch timelines and complicate global supply synchronization.

Policy shifts also elevate the importance of vertical integration and strategic alliances. Companies may pursue long-term supply agreements, co-investments in manufacturing capacity, or regional partnerships to secure critical inputs and maintain continuity of care. Regulatory compatibility across trade partners and clarity on tariff classifications become decisive factors in sourcing decisions. Collectively, these dynamics underscore the need for a proactive, cross-functional response to tariff-driven pressures to safeguard both access and commercial viability.

A multifaceted segmentation analysis connecting routes, indications, drug classes, dosage forms, and age cohorts to inform targeted development and commercialization

A granular segmentation framework illuminates where clinical demand intersects with formulation innovation and commercial strategy, facilitating targeted product development and go-to-market planning. Route of administration distinctions matter because inhalation, injectable, oral, and topical approaches present distinct development, regulatory, and adherence considerations; inhalation modalities further differentiate across dry powder inhaler, metered dose inhaler, and nebulizer platforms, while injectable solutions require attention to intramuscular, intravenous, and subcutaneous delivery nuances. Oral corticosteroids appear in both suspension and tablet formats, each influencing pediatric acceptability and dosing accuracy, whereas topical management leverages creams, lotions, and ointments that vary in absorption and patient preference.

Indication-based segmentation frames therapeutic priorities and evidence requirements; allergic rhinitis and asthma demand robust inhalation and nasal formulations optimized for local efficacy, while dermatological disorders prioritize topical vehicles with favorable safety profiles. Inflammatory bowel disease and rheumatoid arthritis typically necessitate systemic agents with controlled-release characteristics and comprehensive safety monitoring. Drug type segmentation clarifies competitive dynamics and clinical differentiation, with agents such as budesonide, dexamethasone, hydrocortisone, methylprednisolone, and prednisone each carrying distinct pharmacologic profiles and tolerability considerations that influence prescribing behavior.

Dosage form segmentation-cream, injection, suspension, tablet-intersects with route and indication to determine manufacturing complexity and patient experience. Patient age group segmentation, encompassing adult, geriatric, and pediatric cohorts, underscores the need for age-appropriate formulations, palatability for children, and geriatric dosing strategies that account for comorbidities and polypharmacy. Integrating these lenses enables a cohesive approach to lifecycle management, clinical evidence generation, and commercial positioning that aligns product attributes with stakeholder needs.

How regional regulatory diversity, payer structures, and manufacturing footprints drive differentiated market access strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics shape clinical practice patterns, regulatory expectations, and supply chain design, requiring nuanced approaches to market entry and lifecycle management. In the Americas, healthcare systems demonstrate a mix of private and public payer models that prioritize formulary negotiation, real-world outcomes, and supply reliability; this region also hosts significant manufacturing capacity and advanced distribution networks, placing emphasis on differentiated evidence and contract performance. Europe, Middle East & Africa presents heterogeneous regulatory regimes and access pathways, where regional hubs and localized manufacturing can ease market access while clinical guidelines and reimbursement frameworks vary considerably across submarkets. The necessity to address diverse clinician preferences and align with local pharmacovigilance standards is critical in these territories.

Asia-Pacific features a dynamic mix of emerging and mature markets with differing regulatory rigor and cost sensitivities. Rapid urbanization and increasing prevalence of chronic respiratory and dermatologic conditions have created demand for both established and novel corticosteroid therapies, while governments in several jurisdictions are incentivizing local production and technology transfer to reduce import dependence. Across all regions, cross-border supply chain risks, regulatory harmonization efforts, and evolving patient expectations underscore the importance of flexible manufacturing footprints, adaptive pricing models, and targeted evidence generation to support market access and long-term adoption.

Competitive dynamics and strategic capabilities that influence product differentiation, supply continuity, and evidence-driven commercialization in the corticosteroid sector

Industry participants are navigating a competitive environment where therapeutic efficacy, supply reliability, and evidence generation determine commercial success. Established pharmaceutical companies with integrated manufacturing networks leverage scale and regulatory experience to maintain broad portfolios across systemic and local corticosteroid therapies. At the same time, specialized developers and biotech firms concentrate on formulation advances, device integration, and niche indications to carve differentiated value propositions grounded in safety and patient convenience.

Collaboration between commercial teams and clinical development functions is increasingly important, as payers demand robust real-world evidence and outcomes data to justify formulary placement. Strategic partnerships, co-development agreements, and contract manufacturing relationships are common mechanisms to accelerate access to novel delivery systems and alternative dosage forms while managing capital intensity. Additionally, companies are investing in pharmacovigilance, health economics, and patient support programs to reinforce product positioning and sustain adherence in chronic indications. Overall, competitive advantage arises from integrating clinical differentiation with manufacturing agility and rigorous post-market evidence generation.

Practical strategic directives for manufacturers and stakeholders to align innovation, supply resilience, and evidence generation while managing commercial risk

Industry leaders should adopt a proactive strategy that aligns clinical innovation with supply chain resilience and payer expectations. Prioritize investment in formulation platforms and device integration to enhance local delivery, reduce systemic exposure, and improve patient adherence. Simultaneously, strengthen supplier relationships for critical APIs and excipients through multi-sourcing, long-term agreements, and selective vertical integration to mitigate disruption risks and ensure continuity of supply.

Enhance evidence generation by combining randomized trials with pragmatic, real-world studies that capture long-term safety, adherence patterns, and health-economic outcomes. Use these data to support differentiated value propositions in negotiations with payers and healthcare systems. Operationally, implement advanced demand-sensing tools and scenario planning to respond to trade policy shifts and logistical constraints. Lastly, engage in disciplined portfolio management that aligns therapeutic focus with clinical unmet needs and demographic trends, while pursuing strategic partnerships to accelerate time-to-market for novel formulations and delivery systems.

A transparent, triangulated research approach combining clinician interviews, regulatory review, and operational analysis to validate insights across clinical and commercial domains

This research synthesizes primary and secondary evidence to build a comprehensive perspective on corticosteroid therapy across clinical, commercial, and supply chain dimensions. Primary inputs include structured interviews with clinicians across respiratory, dermatology, and gastroenterology specialties, procurement leaders, and regulatory affairs professionals, complemented by closed-door consultations with manufacturing and quality experts. Secondary sources encompass peer-reviewed literature, regulatory guidances, pharmacopoeial standards, and public disclosures related to product approvals and safety communications.

Analytical methods prioritize cross-validation between qualitative insights and documented regulatory frameworks. The approach emphasizes triangulation, where interview-derived observations are tested against published guidance and manufacturing practices to ensure robust interpretation. Scenario analysis is used to examine the operational impact of trade policy shifts on sourcing and distribution, while evidence synthesis focuses on aligning formulation attributes with clinical needs and patient population characteristics. Data governance practices and methodological transparency underpin all findings to ensure reproducibility and practical relevance for decision-makers.

A conclusive synthesis emphasizing the convergence of clinical innovation, evidence-driven commercialization, and supply chain resilience as determinants of future success

Corticosteroid therapy stands at the intersection of enduring clinical utility and accelerating demands for safety, differentiation, and supply security. Progress in formulation and delivery technologies, coupled with evolving clinical stewardship, creates opportunities for targeted innovation that improves patient outcomes while addressing payer and provider priorities. At the same time, geopolitical and trade policy developments have elevated supply chain considerations to a strategic imperative, making resilience a core component of commercial planning.

Decision-makers should therefore balance investments in clinical differentiation with pragmatic initiatives to secure upstream inputs and manufacturing continuity. Evidence generation that articulates real-world benefits and cost implications will be decisive in formulary discussions and long-term adoption. In sum, success will favor organizations that effectively integrate clinical science, regulatory compliance, and operational agility to deliver corticosteroid therapies that meet the needs of patients, clinicians, and health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Impact of targeted inhaled corticosteroid formulations on severe asthma management costs and outcomes
  • 5.2. Emerging small-molecule glucocorticoid receptor modulators aiming to reduce systemic side effects in chronic inflammatory diseases
  • 5.3. Expansion of biosimilar corticosteroid injectables improving access in emerging markets and driving price competition
  • 5.4. Development of nanotechnology-based corticosteroid drug delivery systems for enhanced ocular and dermal therapy efficacy
  • 5.5. Integration of digital health platforms for remote monitoring of biologic corticosteroid therapy adherence in rheumatoid arthritis
  • 5.6. Growing adoption of combination corticosteroid and immunomodulator therapies for atopic dermatitis with improved patient adherence
  • 5.7. Regulatory changes accelerating approval pathways for novel inhaled corticosteroid therapies targeting pediatric asthma populations
  • 5.8. Advancements in gene expression profiling guiding personalized dosing strategies for systemic corticosteroid regimens in autoimmune conditions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Corticosteroids Therapy Market, by Route Of Administration

  • 8.1. Inhalation
    • 8.1.1. Dry Powder Inhaler
    • 8.1.2. Metered Dose Inhaler
    • 8.1.3. Nebulizer
  • 8.2. Injectable
    • 8.2.1. Intramuscular
    • 8.2.2. Intravenous
    • 8.2.3. Subcutaneous
  • 8.3. Oral
    • 8.3.1. Suspension
    • 8.3.2. Tablet
  • 8.4. Topical
    • 8.4.1. Cream
    • 8.4.2. Lotion
    • 8.4.3. Ointment

9. Corticosteroids Therapy Market, by Indication

  • 9.1. Allergic Rhinitis
  • 9.2. Asthma
  • 9.3. Dermatological Disorders
  • 9.4. Inflammatory Bowel Disease
  • 9.5. Rheumatoid Arthritis

10. Corticosteroids Therapy Market, by Drug Type

  • 10.1. Budesonide
  • 10.2. Dexamethasone
  • 10.3. Hydrocortisone
  • 10.4. Methylprednisolone
  • 10.5. Prednisone

11. Corticosteroids Therapy Market, by Dosage Form

  • 11.1. Cream
  • 11.2. Injection
  • 11.3. Suspension
  • 11.4. Tablet

12. Corticosteroids Therapy Market, by Patient Age Group

  • 12.1. Adult
  • 12.2. Geriatric
  • 12.3. Pediatric

13. Corticosteroids Therapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Corticosteroids Therapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Corticosteroids Therapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. GlaxoSmithKline plc
    • 16.3.2. AstraZeneca plc
    • 16.3.3. Novartis AG
    • 16.3.4. Sanofi S.A.
    • 16.3.5. Merck & Co., Inc.
    • 16.3.6. Pfizer Inc.
    • 16.3.7. Teva Pharmaceutical Industries Ltd
    • 16.3.8. Sun Pharmaceutical Industries Ltd
    • 16.3.9. Mylan N.V.
    • 16.3.10. Sandoz International GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CORTICOSTEROIDS THERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CORTICOSTEROIDS THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CORTICOSTEROIDS THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRY POWDER INHALER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRY POWDER INHALER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRY POWDER INHALER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRY POWDER INHALER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY METERED DOSE INHALER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY METERED DOSE INHALER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY METERED DOSE INHALER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY METERED DOSE INHALER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY METERED DOSE INHALER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY METERED DOSE INHALER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY NEBULIZER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY NEBULIZER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY NEBULIZER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY NEBULIZER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY NEBULIZER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUSPENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUSPENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY CREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY CREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY CREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY CREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY CREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY LOTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY LOTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY LOTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY LOTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY LOTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY LOTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY OINTMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY OINTMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY OINTMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY OINTMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY OINTMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY OINTMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ALLERGIC RHINITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ALLERGIC RHINITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ALLERGIC RHINITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ALLERGIC RHINITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ASTHMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ASTHMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ASTHMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ASTHMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ASTHMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ASTHMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DERMATOLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DERMATOLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DERMATOLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DERMATOLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DERMATOLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DERMATOLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY BUDESONIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY BUDESONIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY BUDESONIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY BUDESONIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY BUDESONIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY BUDESONIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY HYDROCORTISONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY HYDROCORTISONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY HYDROCORTISONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY HYDROCORTISONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY HYDROCORTISONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY HYDROCORTISONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY METHYLPREDNISOLONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY METHYLPREDNISOLONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY METHYLPREDNISOLONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY METHYLPREDNISOLONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PREDNISONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PREDNISONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PREDNISONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PREDNISONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PREDNISONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PREDNISONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY CREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY CREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY CREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY CREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY CREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUSPENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUSPENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST CORTICOSTEROIDS THERAPY MAR